2020 North American Menopause Society (NAMS) Virtual Annual Meeting

05 October 2020 - 09 October 2020

Novel non-hormonal therapy may reduce hot flashes, improve QoL in postmenopausal women

21 Oct 2020 by

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.

Novel non-hormonal therapy may reduce hot flashes, improve QoL in postmenopausal women

21 Oct 2020

Number, severity of menopausal symptoms may up CV risk

19 Oct 2020 by

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.

Number, severity of menopausal symptoms may up CV risk

19 Oct 2020

Midlife women still desire a home run

13 Oct 2020 by

Contrary to the common belief that women’s interest in sex fades as they age, a study presented at NAMS 2020 revealed that about 25 percent of women in their midlife continue to rate sex as important.

Midlife women still desire a home run

13 Oct 2020

Suvorexant beneficial for VMS-associated insomnia in midlife women

13 Oct 2020 by

The dual orexin receptor antagonist suvorexant was effective in managing VMS*-associated insomnia among women in midlife, with further benefits for self-reported night-time, but not daytime, VMS, according to data presented at NAMS 2020.

Suvorexant beneficial for VMS-associated insomnia in midlife women

13 Oct 2020

Vaginal softgel benefits older women with vulvovaginal atrophy

12 Oct 2020 by

Use of the self-administered TX-004HR – an applicator-free, ultra-low-dose, 17β-oestradiol softgel vaginal insert – led to significant improvements in the symptoms of vulvovaginal atrophy (VVA) such as moderate-to-severe dyspareunia and vaginal dryness in postmenopausal women aged >60 years, according to updated results from the phase III REJOICE trial presented at NAMS 2020.

Vaginal softgel benefits older women with vulvovaginal atrophy

12 Oct 2020

Hormone therapy protects the heart by lowering inflammation

10 Oct 2020 by

One way how hormone therapy with oestradiol may slow the progression of atherosclerotic cardiovascular disease (CVD) in postmenopausal women is through the reduction of inflammatory biomarkers, according to the ELITE* study presented at the NAMS 2020 Annual Meeting.

Hormone therapy protects the heart by lowering inflammation

10 Oct 2020